{"id":18698,"date":"2026-06-10T11:00:00","date_gmt":"2026-06-10T09:00:00","guid":{"rendered":"http:\/\/stocks-future.com\/?guid=d64605a92e2024719812b27aaffc48b9"},"modified":"2026-06-10T11:00:00","modified_gmt":"2026-06-10T09:00:00","slug":"abl-diagnostics-abld-announces-the-submission-of-a-takeover-bid-for-texcell-france","status":"publish","type":"post","link":"https:\/\/stocks-future.com\/?p=18698","title":{"rendered":"ABL Diagnostics (ABLD) Announces the Submission of a Takeover Bid for Texcell France"},"content":{"rendered":"<p>WOIPPY, France--(BUSINESS WIRE)--Regulatory News:<\/p><p>\nABL Diagnostics (Paris:ABLD) (Euronext Paris \u2013 Compartment B \u2013 ISIN: FR001400AHX6), a company specialized in molecular diagnostic solutions, healthcare software, and clinical sample management, announces that on Tuesday, June 9, 2026, it submitted a bid to acquire the business and assets of TEXCELL, a company specialized in viral safety testing, immunology, and R&amp;D services for biopharmaceutical products, currently subject to judicial reorganization proceedings before the Commercial Court of \u00c9vry.<\/p><p>\nThis initiative is part of ABL Diagnostics\u2019 development strategy aimed at assessing external growth opportunities complementary to its current portfolio.<\/p><p>\nThis proposed acquisition, based on Article L. 642-1 of the French Commercial Code, remains subject to the decision of the Commercial Court of \u00c9vry. At this stage, there is no certainty as to the outcome of these insolvency proceedings.<\/p><p>\nThe Company will keep the market informed of any significant developments regarding this matter, in accordance with applicable regulatory obligations.<\/p><p>\n<b>Regulated information:<\/b> <i>This press release contains inside information within the meaning of Article 7 of Regulation (EU) No 596\/2014 (Market Abuse Regulation \u2013 MAR). Its dissemination is carried out in accordance with Article 17 of MAR. The forward-looking statements contained in this document are inherently subject to risks and uncertainties, particularly those related to the outcome of legal proceedings and third-party approvals.<\/i><\/p><p>\n<b>About ABL Diagnostics (ABLD)<\/b><\/p><p>\nABL Diagnostics (ABLD) is an international company that specializes in innovative molecular biology tests and global solutions for its customers:<\/p><ul class=\"bwlistdisc\">\n<li>\nMolecular polymerase chain reaction (PCR) detection \u2013 UltraGene, and<\/li>\n<li>\nGenotyping by DNA sequencing \u2013 DeepChek<sup>\u00ae<\/sup>.<\/li>\n<\/ul><p>\nABL Diagnostics markets its entire product range globally through its own sales team and a network of exclusive distributors active on all continents. ABL Diagnostics' customers are academic clinical pathology laboratories, private reference laboratories and researchers willing to implement innovative and robust microbiological content in constant expansion.<\/p><p>\nABL Diagnostics has been marketing the products and services of its sister company CDL Pharma since the second half of 2025 through an intra-group strategy agreement.<\/p><p>\n<b>An expanding portfolio of microbiology products:<\/b><\/p><ul class=\"bwlistdisc\">\n<li>\nHIV \u2013 Drug resistance testing, including a whole genome kit.<\/li>\n<li>\nSARS-CoV-2, Tuberculosis, Hepatitis B and C \u2013 Advanced Detection Solutions.<\/li>\n<li>\nMicrobiome and taxonomy \u2013 16s\/18s RNA-based analyses.<\/li>\n<li>\nOther viral and bacterial targets \u2013 Comprehensive molecular assays.<\/li>\n<\/ul><p>\n<b>Integrated Solutions<\/b><\/p><ul class=\"bwlistdisc\">\n<li>\nReal-time syndromic PCR tests<\/li>\n<li>\nNadis<sup>\u00ae<\/sup> \u2013 Patient Medical Record used in more than 200 hospitals in France for the management of HIV and hepatitis.<\/li>\n<li>\nMediaChek<sup>\u00ae<\/sup> \u2013 Clinical Sample Collection Kits.<\/li>\n<\/ul><p>\nABL Diagnostics, headquartered in Woippy, is a public limited company listed on compartment B of the regulated market of Euronext in Paris (Euronext: ABLD \u2013 ISIN: FR001400AHX6). These molecular biology products generate recurring revenues and cover one of the largest portfolios of applications in microbiology.<\/p><br\/> <b>Contacts<\/b> <br\/><p>\n<b>ABL Diagnostics SA<\/b><br\/>Soci\u00e9t\u00e9 anonyme au capital de 1 611 465,60 euros\n<br\/>Headquarters : 72C route de Thionville - 57140 WOIPPY\n<br\/>552 064 933 R.C.S. METZ<\/p><p>\nTel : +33 (0)7 83 64 68 50\n<br\/>Email : <a  href=\"mailto:info@abldiagnostics.com\" rel=\"nofollow\" shape=\"rect\">info@abldiagnostics.com<\/a><br\/><a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.abldiagnostics.com%2F&amp;esheet=54550958&amp;newsitemid=20260609710415&amp;lan=en-US&amp;anchor=https%3A%2F%2Fwww.abldiagnostics.com%2F&amp;index=1&amp;md5=99ce2b00355f8ab1e3828360a0b157bd\" rel=\"nofollow\" shape=\"rect\">https:\/\/www.abldiagnostics.com\/<\/a><\/p>","protected":false},"excerpt":{"rendered":"<p>WOIPPY, France&#8211;(BUSINESS WIRE)&#8211;Regulatory News:<br \/>\nABL Diagnostics (Paris:ABLD) (Euronext Paris \u2013 Compartment B \u2013 ISIN: FR001400AHX6), a company specialized in molecular diagnostic solutions, healthcare software, and clinical sample management, announce&#8230;<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-18698","post","type-post","status-publish","format-standard","hentry","category-infos-businesswire"],"_links":{"self":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/18698","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=18698"}],"version-history":[{"count":1,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/18698\/revisions"}],"predecessor-version":[{"id":18699,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/18698\/revisions\/18699"}],"wp:attachment":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=18698"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=18698"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=18698"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}